Nektar Therapeutics (NKTR) is implementing a cost restructuring plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/30/2026
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Wall Street closes down sharply after Fed holds rates unchanged
- How will the S&P 500 react to today’s FOMC? JPM lays out the playbook
- Grant Thornton Advisors to buy CBIZ in $5 billion deal, expand US accounting reach
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook
April 25, 2022 4:30 PM EDTCompany focusing on key pipeline programs NKTR-358, NKTR-255 and core research programs
Cost restructuring plan results in cash runway into the first half of 2025
Analyst and investor conference call today at 5:00 PM ET (2:00 PM PT)
SAN FRANCISCO, April 25, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced a new strategic plan focused on prioritizing key research and development efforts that will be most impactful to the company's... More
